{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:33Z","timestamp":1792513113413,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2018YFC0114600"],"award-info":[{"award-number":["2018YFC0114600"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170547"],"award-info":[{"award-number":["82170547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04372-2","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T22:34:21Z","timestamp":1764369261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insights into the treatment of infliximab and vedolizumab in positive PR3-ANCA patients with moderately to severely active ulcerative colitis: multicenter real-world evidence"],"prefix":"10.1186","volume":"25","author":[{"given":"Qi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangru","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"10401","key":"4372_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402(10401):571\u201384.","journal-title":"Lancet"},{"issue":"1","key":"4372_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. Ecco guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"4372_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02347-1","volume":"22","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, et al. Comparative efficacy and safety of Infliximab and Vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol. 2022;22(1):291.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"4372_CR4","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network Meta-Analysis. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2020;18(10):2179\u2013e21912176.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"2","key":"4372_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"4372_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1007\/s10620-023-08252-1","volume":"69","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Bossuyt P, Bettenworth D, Loftus EV Jr., Anjie SI, D\u2019Haens G, et al. Comparative efficacy of subcutaneous and intravenous Infliximab and Vedolizumab for maintenance treatment of TNF-naive adult patients with inflammatory bowel disease: a systematic literature review and network meta-analysis. Dig Dis Sci. 2024;69(5):1808\u201325.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"4372_CR7","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.cgh.2021.07.038","volume":"20","author":"N Narula","year":"2022","unstructured":"Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W. Comparative efficacy for Infliximab vs Vedolizumab in biologic Naive ulcerative colitis. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2022;20(7):1588\u2013e15971583.","journal-title":"Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association"},{"issue":"1","key":"4372_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28907-3","volume":"13","author":"R Sablich","year":"2023","unstructured":"Sablich R, Urbano MT, Scarpa M, Scognamiglio F, Paviotti A, Savarino E. Vedolizumab is superior to Infliximab in biologic na\u00efve patients with ulcerative colitis. Sci Rep. 2023;13(1):1816.","journal-title":"Sci Rep"},{"key":"4372_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241281218","volume":"17","author":"Z Huang","year":"2024","unstructured":"Huang Z, Tang J, Wu R, Long S, Chen W, Lu T, et al. Comparison of clinical and endoscopic efficacy between Vedolizumab and Infliximab in bio-na\u00efve patients with ulcerative colitis: a multicenter, real-world study. Ther Adv Gastroenterol. 2024;17:17562848241281218.","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"4372_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02938-6","volume":"23","author":"X Chu","year":"2023","unstructured":"Chu X, Biao Y, Liu C, Zhang Y, Liu C, Ma JZ, et al. Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis. BMC Gastroenterol. 2023;23(1):346.","journal-title":"BMC Gastroenterol"},{"key":"4372_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14140","author":"H Takedatsu","year":"2018","unstructured":"Takedatsu H, Mitsuyama K, Fukunaga S, Yoshioka S, Yamauchi R, Mori A, et al. Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease. J Gastroenterol Hepatol. 2018. https:\/\/doi.org\/10.1111\/jgh.14140.","journal-title":"J Gastroenterol Hepatol"},{"issue":"45","key":"4372_CR12","doi-asserted-by":"publisher","first-page":"7012","DOI":"10.3748\/wjg.14.7012","volume":"14","author":"J Xu","year":"2008","unstructured":"Xu J, Yang CH, Chen XY, Li XH, Dai M, Xiao SD. A subset of ulcerative colitis with positive proteinase-3 antineutrophil cytoplasmic antibody. World J Gastroenterol. 2008;14(45):7012\u20135.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4372_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/00054725-199911000-00002","volume":"5","author":"AN Elzouki","year":"1999","unstructured":"Elzouki AN, Eriksson S, L\u00f6fberg R, N\u00e4ssberger L, Wieslander J, Lindgren S. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis. 1999;5(4):246\u201352.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"4372_CR14","first-page":"169","volume":"21","author":"A Garc\u00eda-Herola","year":"1998","unstructured":"Garc\u00eda-Herola A, Nos P, Hoyos M, Hinojosa J, Mol\u00e9s JR, Pascual S, Bustamante M, S\u00e1nchez Cuenca JM, Carmona E, Ponce J, et al. [Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and crohn\u2019s disease]. Gastroenterol Hepatol. 1998;21(4):169\u201373.","journal-title":"Gastroenterol Hepatol"},{"issue":"4","key":"4372_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ajg.2023.07.001","volume":"24","author":"J Zeng","year":"2023","unstructured":"Zeng J, Gao X, Ge W, Huai M, Yang Z, Luo T, et al. Development of a scoring system for predicting the severity of ulcerative colitis. Arab J Gastroenterol. 2023;24(4):211\u20137.","journal-title":"Arab J Gastroenterol"},{"issue":"1","key":"4372_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01903-5","volume":"21","author":"Y Aoyama","year":"2021","unstructured":"Aoyama Y, Inaba T, Takahashi S, Yasuhara H, Hiraoka S, Morimoto T, et al. Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterol. 2021;21(1):325.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"4372_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5009\/gnl210211","volume":"16","author":"S Imakiire","year":"2022","unstructured":"Imakiire S, Takedatsu H, Mitsuyama K, Sakisaka H, Tsuruta K, Morita M, et al. Role of serum proteinase 3 antineutrophil cytoplasmic antibodies in the diagnosis, evaluation of disease severity, and clinical course of ulcerative colitis. Gut Liver. 2022;16(1):92\u2013100.","journal-title":"Gut Liver"},{"key":"4372_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cca.2013.06.005","volume":"424","author":"M Mahler","year":"2013","unstructured":"Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Damoiseaux J, et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta. 2013;424:267\u201373.","journal-title":"Clin Chim Acta"},{"key":"4372_CR19","doi-asserted-by":"crossref","unstructured":"Wen C, Hu H, Yang W, Zhao Y, Zheng L, Jiang X, Wang L. Targeted Inhibition of FcRn reduces NET formation to ameliorate experimental ulcerative colitis by accelerating ANCA clearance. Int Immunopharmacol 2022, 113(Pt B):109474.","DOI":"10.1016\/j.intimp.2022.109474"},{"issue":"2","key":"4372_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000515361","volume":"6","author":"A Yoshida","year":"2021","unstructured":"Yoshida A, Matsuoka K, Ueno F, Morizane T, Endo Y, Hibi T. Serum PR3-ANCA is a predictor of primary nonresponse to anti-TNF-\u03b1 agents in patients with ulcerative colitis. Inflamm Intest Dis. 2021;6(2):117\u201322.","journal-title":"Inflamm Intest Dis"},{"issue":"4","key":"4372_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/MEG.0000000000001356","volume":"31","author":"C Liefferinckx","year":"2019","unstructured":"Liefferinckx C, Minsart C, Cremer A, Amininejad L, Tafciu V, Quertinmont E, et al. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Eur J Gastroenterol Hepatol. 2019;31(4):478\u201385.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"4372_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ibd.20054","volume":"13","author":"M Ferrante","year":"2007","unstructured":"Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to Infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13(2):123\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"4372_CR23","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/ajg.2010.95","volume":"105","author":"M J\u00fcrgens","year":"2010","unstructured":"J\u00fcrgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, et al. Disease activity, ANCA, and IL23R genotype status determine early response to Infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105(8):1811\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"4372_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2025.2489025","volume":"36","author":"W Chen","year":"2025","unstructured":"Chen W, Ding Y, Cai L, Xue M, Arif AR, Mei H, et al. Platelet parameters for distinguishing between inherited macrothrombocytopenia and acquired thrombocytopenia: a retrospective case-control study. Platelets. 2025;36(1):2489025.","journal-title":"Platelets"},{"issue":"2","key":"4372_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S2468-1253(21)00294-6","volume":"7","author":"S Danese","year":"2022","unstructured":"Danese S, Colombel JF, Lukas M, Gisbert JP, D\u2019Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, et al. Etrolizumab versus Infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022;7(2):118\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"4372_CR26","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/S2665-9913(24)00035-3","volume":"6","author":"SD Falde","year":"2024","unstructured":"Falde SD, Fussner LA, Tazelaar HD, O\u2019Brien EK, Lamprecht P, Konig MF, et al. Proteinase 3-specific antineutrophil cytoplasmic antibody-associated vasculitis. Lancet Rheumatol. 2024;6(5):e314-27.","journal-title":"Lancet Rheumatol"},{"key":"4372_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105779","volume":"171","author":"A Dos Santos Ramos","year":"2021","unstructured":"Dos Santos Ramos A, Viana GCS, de Macedo Brigido M, Almeida JF. Neutrophil extracellular traps in inflammatory bowel diseases: implications in pathogenesis and therapeutic targets. Pharmacol Res. 2021;171:105779.","journal-title":"Pharmacol Res"},{"issue":"8","key":"4372_CR28","volume":"2014","author":"SJ Bickston","year":"2014","unstructured":"Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, MacDonald JK, Khanna R, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;2014(8):Cd007571.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"4372_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2567.2009.03108.x","volume":"128","author":"A Hussain","year":"2009","unstructured":"Hussain A, Pankhurst T, Goodall M, Colman R, Jefferis R, Savage CO, et al. Chimeric IgG4 PR3-ANCA induces selective inflammatory responses from neutrophils through engagement of Fcgamma receptors. Immunology. 2009;128(2):236\u201344.","journal-title":"Immunology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04372-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04372-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04372-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:27:06Z","timestamp":1767072426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04372-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4372"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04372-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the principles of the Declaration of Helsinki. The study was reviewed and approved by the Ethics Committee of Union Hospital (Ethics Review Number 2024-No.0532).The Ethics Committee of Union Hospital waived the requirement for participant consent due to the retrospective nature of the study and the use of anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"891"}}